Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 556 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene sequencing Clear all
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

NCT02610426
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging Biomarkers of Pancreatic Function and Disease

NCT05659147
View directory record Official record
Conditions
Pancreatitis, Diabetes Mellitus
Interventions
Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin
Diagnostic Test · Genetic · Other + 1 more
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Withdrawn No phase listed Observational

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

NCT03749083
View directory record Official record
Conditions
Gastrointestinal Malignancies
Interventions
The Functional Assessment of Cancer Therapy- Colorectal
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Timeline
2019 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 31, 2026, 2:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Genetic Inclusion by Virtual Evaluation

NCT05318222
View directory record Official record
Conditions
Birth Defects, Multiple Congenital Anomaly, Neurodevelopmental Disorders
Interventions
Whole genome sequencing (WGS)
Diagnostic Test
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 18 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions

NCT01457196
View directory record Official record
Conditions
Neoplasm
Interventions
Tumor Genetic Sequencing
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 31, 2026, 2:03 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing

NCT04574752
View directory record Official record
Conditions
Staphylococcus Aureus, Next Generation Sequencing, Total Joint Arthroplasty
Interventions
next generation sequencing
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 31, 2026, 2:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage

NCT02121873
View directory record Official record
Conditions
Breast Cancer, Preneoplastic Conditions, Ductal Carcinoma in Situ
Interventions
Nipple aspirator, Ductal lavage microcatheter, Blood draw
Device
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 31, 2026, 2:03 PM EDT
Completed No phase listed Observational

MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)

NCT06181669
View directory record Official record
Conditions
Pneumonia, Bacterial, Ventilator Associated Pneumonia
Interventions
Pathogen and Host Directed testing
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Royal Oak, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

Single Embryo TrAnsfeR of Euploid Embryo

NCT02268786
View directory record Official record
Conditions
Infertility, Aneuploidy
Interventions
Preimplantation Genetic Screening by NGS
Other
Lead sponsor
Illumina, Inc.
Industry
Eligibility
25 Years to 40 Years · Female only
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Laguna Niguel, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 31, 2026, 2:03 PM EDT
Recruiting Early Phase 1 Interventional

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

NCT06435351
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Leukapheresis, Dendritic Cell (DC) Vaccine
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

NCT06930495
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Weight loss SOC Treatment with second generation anti-diabetic medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Terminated Phase 1 Interventional

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

NCT01045928
View directory record Official record
Conditions
Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
lenalidomide, rituximab, polymerase chain reaction, nucleic acid sequencing, polymorphism analysis, flow cytometry, laboratory biomarker analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 31, 2026, 2:03 PM EDT
Completed No phase listed Observational

Pregnant Women s Views About the Ethics of Prenatal Whole Genome Sequencing

NCT03105492
View directory record Official record
Conditions
Pregnant
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 31, 2026, 2:03 PM EDT
Completed No phase listed Observational

Rapid Identification of Key Pathogens in Wound Infection by Molecular Means

NCT00287599
View directory record Official record
Conditions
Postoperative Wound Infection, Traumatic Wound Infection, Closed Soft Tissue Abscess
Interventions
Not listed
Lead sponsor
Brentwood Biomedical Research Institute
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT03389347
View directory record Official record
Conditions
Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
Procedure · Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 2:03 PM EDT
Completed No phase listed Observational

Transition of Renal Patients Using AlloSure Into Community Kidney Care

NCT04601155
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AlloSure
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Fairfield, California • Fresno, California • Granada Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moderate Aerobic Activity Through Yoga

NCT05184673
View directory record Official record
Conditions
Physical Activity
Interventions
Behavioral and environmental
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
65 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional

Ohio Colorectal Cancer Prevention Initiative

NCT01850654
View directory record Official record
Conditions
Lynch Syndrome, Colorectal Cancer
Interventions
LS tumor screening, Genetic testing, Genetic Counseling, Biorepository, Questionnaire
Genetic · Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
49
States / cities
Akron, Ohio • Barberton, Ohio • Batavia, Ohio + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 31, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)

NCT03890679
View directory record Official record
Conditions
Pediatric: Genetic Syndrome
Interventions
rapid whole genomic sequencing (rWGS)
Diagnostic Test
Lead sponsor
Tufts Medical Center
Other
Eligibility
1 Day to 1 Year
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 31, 2026, 2:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

NCT04170985
View directory record Official record
Conditions
Neurologic Deficits, Neurologic Disorder, Neurologic Abnormalities
Interventions
clinical Whole Genome Sequencing
Other
Lead sponsor
Illumina, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 31, 2026, 2:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

NCT05469178
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Bemcentinib, Pembrolizumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 31, 2026, 2:03 PM EDT
Terminated No phase listed Observational

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

NCT04791215
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Observational
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 31, 2026, 2:03 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

NCT06441955
View directory record Official record
Conditions
COVID-19, Long Haul
Interventions
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
Drug · Diagnostic Test · Biological + 3 more
Lead sponsor
Well- Konnect Healthcare Services and Research Firm
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 31, 2026, 2:03 PM EDT